Performance of a new HPV and biomarker assay in the management of hrHPV positive women: Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer-Reference-Cited by-同舟云学术

Performance of a new HPV and biomarker assay in the management of hrHPV positive women: Subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer

Published:2017-01-18 Issue:5 Volume:140 Page:1119-1133
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Kocsis Adrienn¹²,Takács Tibor¹²³,Jeney Csaba⁴,Schaff Zsuzsa⁵,Koiss Róbert⁶,Járay Balázs⁵,Sobel Gábor⁷,Pap Károly⁸,Székely István⁶,Ferenci Tamás⁹,Lai Hung-Cheng¹⁰¹¹,Nyíri Miklós¹²,Benczik Márta¹²³

Affiliation:

1. NEUMANN Diagnostics Ltd.; Budapest Hungary

2. Cellcall Ltd.; Budapest Hungary

3. SYNLAB Hungary Ltd.; GenoID Molecular Diagnostic Laboratory; Budapest Hungary

4. Institute of Medical Microbiology, Semmelweis University; Budapest Hungary

5. Second Department of Pathology; Semmelweis University; Budapest Hungary

6. Department of Obstetrics and Gynaecology; St. Stephan Hospital; Budapest Hungary

7. Second Department of Obstetrics and Gynaecology; Semmelweis University; Budapest Hungary

8. Jósa András Regional Central Hospital; Nyíregyháza Hungary

9. Óbuda University; Budapest Hungary

10. Department of Obstetrics and Gynecology; Shuang Ho Hospital, Taipei Medical University; Taipei Taiwan

11. Department of Obstetrics and Gynecology, School of Medicine, College of Medicine; Taipei Medical University; Taipei Taiwan

Funder

New Hungary Development Plan, Hungarian Government

SYSTEMCERV, FP7 SME-targeted Collaborative Project, EU

Cellcall Ltd., Budapest, Hungary

NEUMANN Diagnostics Ltd., Budapest, Hungary

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference49 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2012

2. Cervical cancer screening in the 21st century: is it time to retire the PAP smear?;Wright;Clin Obstet Gynecol,2007

3. Overview of the European and North American studies on HPV testing in primary cervical cancer screening;Cuzick;Int J Cancer,2006

4. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts;Sahasrabuddhe;Future Microbiol,2011

5. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance;Huh;Gynecol Oncol,2015

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HPV16-miRNAs exert oncogenic effects through enhancers in human cervical cancer;Cancer Cell International;2024-05-15

2. Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries;Clinical Epigenetics;2024-04-20

3. Epigenetic biomarkers in personalized medicine;Personalized Epigenetics;2024

4. High-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries;2023-12-12

5. HPV16-miRNAs Exert Oncogenic Effects through Enhancers in Human Cervical Cancer;2023-12-07